Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients

Clinical Chemistry

Volumn 59, Issue 12, 2013, Pages 1722-1731

  Taly, Valerie ^a   Pekin, Deniz ^a,b   Benhaim, Leonor ^a   Kotsopoulos, Steve K ^c   Corre, Delphine Le ^a   Li, Xinyu ^c   Atochin, Ivan ^c   Link, Darren R ^c   Griffiths, Andrew D ^b,d   Pallier, Karine ^a   Blons, Hélène ^a   Bouché, Olivier ^e   Landi, Bruno ^f   Hutchison, J Brian ^c   Laurent Puig, Pierre ^a,f  

^a Therapeutic Implications Laboratoire d'Excellence GR Ex   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c RainDance Technologies   (United States)

^d CNRS   (France)

^e SERVICE DE DERMATOLOGIE   (France)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

ADULT; ARTICLE; BRAF GENE; CLINICAL ARTICLE; CODON; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FALSE POSITIVE RESULT; FEMALE; GENE; GENE MUTATION; GENETIC SCREENING; HUMAN; HUMAN TISSUE; KRAS GENE; MALE; METASTASIS; MULTIPLEX PICODROPLET DIGITAL POLYMERASE CHAIN REACTION; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATIONAL ANALYSIS; NON INVASIVE PROCEDURE; ONCOGENE; PLASMA; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; WILD TYPE;

BASE SEQUENCE; COLORECTAL NEOPLASMS; DNA; DNA PRIMERS; GENES, RAS; HUMANS; LIMIT OF DETECTION; MUTATION; POLYMERASE CHAIN REACTION;

EID: 84884176329     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2013.206359     Document Type: Article

References (40)

1. Negm RS, Verma M, Srivastava S. The promise of biomarkers in cancer screening and detection. Trends Mol Med 2002;8:288-93
2. Sawyers CL. The cancer biomarker problem. Nature 2008;452:548-52
3. van't Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of geneexpression patterns. Nature 2008;452:564-70
4. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-9
5. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009;27:5924-30
6. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-5
7. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010;28:466-74
8. Lecomte T, Berger A, Zinzindohoue F, Micard S, Landi B, Blons H, et al. Detection of freecirculating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer 2002;100:542-8
9. Aung KL, Board RE, Ellison G, Donald E, Ward T, Clack G, et al. Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours. HUGO J 2010;4:11-21
10. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011;11:426-37
11. Higgins MJ, Jelovac D, Barnathan E, Blair B, Slater S, Powers P, et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res 2012;18:3462-9
12. Stratton MR. Exploring the genomes of cancer cells: progress and promise. Science 2011;331: 1553-8
13. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008;14:985-90
14. Ludwig JA,Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005;5:845-56
15. Sykes PJ, Neoh SH, Brisco MJ, Hughes E, Condon J, Morley AA. Quantitation of targets for PCR by use of limiting dilution. Biotechniques 1992;13: 444-9
16. Vogelstein B, Kinzler KW. Digital PCR. Proc Natl Acad Sci U S A 1999;96:9236-41
17. Baker M. Digital PCR hits its stride. Nat Methods 2012;9:541-4
18. Taly V, Pekin D, Abed AE, Laurent-Puig P. Detecting biomarkers with microdroplet technology. Trends Mol Med 2012;18:405-16
19. Dressman D, Yan H, Traverso G, Kinzler KW, Vogelstein B. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A 2003;100:8817-22
20. Nakano M, Komatsu J, Matsuura S, Takashima K, Katsura S, Mizuno A. Single-molecule PCR using water-in-oil emulsion. J Biotechnol 2003;102: 117-24
21. Theberge AB, Courtois F, Schaerli Y, Fischlechner M, Abell C, Hollfelder F, et al. Microdroplets in microfluidics: an evolving platform for discoveries in chemistry and biology. Angew Chem Int Ed Engl 2010;49:5846-68
22. Pekin D, Skhiri Y, Baret JC, Le Corre D, Mazutis L, Ben Salem C, et al. Quantitative and sensitive detection of rare mutations using droplet-based microfluidics. Lab Chip 2011;11:2156-66
23. Hindson BJ, Ness KD, Masquelier DA, Belgrader P, Heredia NJ, Makarewicz AJ, et al. Highthroughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem 2011;83:8604-10
24. Pinheiro LB, Coleman VA, Hindson CM, Herrmann J, Hindson BJ, Bhat S, et al. Evaluation of a droplet digital polymerase chain reaction format for DNA copy number quantification. Anal Chem 2012;84:1003-11
25. Hatch AC, Fisher JS, Tovar AR, Hsieh AT, Lin R, Pentoney SL, et al. 1-Million droplet array with wide-field fluorescence imaging for digital PCR. Lab Chip 2011;11:3838-45
26. Zhong Q, Bhattacharya S, Kotsopoulos S, Olson J, Taly V, Griffiths AD, et al. Multiplex digital PCR: breaking the one target per color barrier of quan-titative PCR. Lab Chip 2011;11:2167-74
27. Russo A, Bazan V, Agnese V, Rodolico V, Gebbia N. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. Ann Oncol 2005; 16(Suppl 4):iv44-9
28. Didelot A, Le Corre D, Luscan A, Cazes A, Pallier K, Emile JF, et al. Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. Exp Mol Pathol 2012;92:275-80
29. Garvin AM, Bottinelli M, Gola M, Conti A, Soldati G. DNA preparation from sexual assault cases by selective degradation of contaminating DNA from the victim. J Forensic Sci 2009; 54:1297-303
30. Didelot A, Kotsopoulos SK, Lupo A, Pekin D, Li X, Atochin I, et al. Multiplex picoliter-droplet digital PCR for quantitative assessment of DNA integrity in clinical samples. Clin Chem 2013; 59:815-23
31. Gormally E, Caboux E, Vineis P, Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res 2007;635:105-17
32. Spindler KL, Pallisgaard N, Vogelius I, Jakobsen A. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res 2012; 18:1177-85
33. Taniguchi K, Uchida J, Nishino K, Kumagai T, Okuyama T, Okami J, et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res 2011;17:7808-15
34. Knijn N, Mekenkamp LJ, Klomp M, Vink-Borger ME, Tol J, Teerenstra S, et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 2011;104:1020-6
35. Santini D, Loupakis F, Vincenzi B, Floriani I, Stasi I, Canestrari E, et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist 2008;13:1270-5
36. Szpechcinski A, Struniawska R, Zaleska J, Chabowski M, Orlowski T, Roszkowski K, et al. Evaluation of fluorescence-based methods for total vs. amplifiable DNA quantification in plasma of lung cancer patients. J Physiol Pharmacol 2008;59(Suppl 6):675-81
37. Bozic I, Allen B, Nowak MA. Dynamics of targeted cancer therapy. Trends Mol Med 2012;18: 311-6
38. Yost SE, Smith EN, Schwab RB, Bao L, Jung H, Wang X, et al. Identification of high-confidence somatic mutations in whole genome sequence of formalin-fixed breast cancer specimens. Nucleic Acids Res 2012;40:e107
39. Richardson AL, Iglehart JD. BEAMing up personalized medicine: mutation detection in blood. Clin Cancer Res 2012;18:3209-11
40. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012;486:537-40